Drugs / J2H-1702
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06308874 | Jan → Feb 2023 | metabolic dysfunction-associated steatohepatitis | J2H Biotech | Completed | No outcome recorded |
| Phase 1 | NCT06308861 | Aug 2020 → Jun 2021 | metabolic dysfunction-associated steatohepatitis | J2H Biotech | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06297434 | Feb 2023 → Jun 2025 | metabolic dysfunction-associated steatohepatitis | J2H Biotech | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | J2H-1702 | “To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men.” NCT06308861 ↗ |
| Route | Oral | “Orally, once daily before meals” NCT06297434 ↗ |